February 3, 2021
Highmark, a Blue Cross Blue Shield-affiliated health insurer, will expand access to Freespira's digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms.
In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from...
February 2, 2021
January 29, 2021
The alarming scale of the opioid use disorder (OUD) epidemic has resulted in unprecedented human and economic devastation, and there is significant opportunity for digital tools to alter the gold standard of care to one that is ongoing and on-demand.
The epidemic has only worsened since the onset of COVID-19, given heightened economic instability, social isolation, disruption to transportation...
January 28, 2021
23andMe's new COVID-19 resource. Consumer genomics company 23andMe has released a new interactive tool that allows users to see how various health factors could impact the risk of COVID-19 hospitalization. The COVID-19 Severity Calculator pulls data from the company's COVID-19 study, which included 10,000 participants diagnosed with the disease and 750 who were hospitalized.
23andMe warned that...
January 22, 2021
Clinical trials have become big news this year amid the search for COVID-19 vaccines and treatments. They are a critical component of helping the FDA validate that new drugs and diagnostics will be both safe and effective.
Pharmaceutical companies spend over $45B a year running clinical trials, which are, by design, very methodical and measured. Unfortunately, they are also slow, unpredictable...
January 15, 2021
Earlier this week DTx company Pear Therapeutics inked a deal with adherence tool etectRx to potentially develop a product that combines the former’s digital therapeutics with a digital pill offering. As part of the deal the two companies will meet quarterly to discuss potential collaborations with the pharma industry.
“Here we are talking about how can we bring this to pharma... we are going to...
January 13, 2021
January 13, 2021
Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture.
The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
January 11, 2021
Biogen has announced a new multiyear research study on cognitive decline that will be conducted using the Apple Watch and iPhone.
The observational study is being conducted in collaboration with Apple, according to the announcement, and is set to kick off later this year. The project's primary goal is to establish digital biomarkers for monitoring long-term cognitive performance and to spot early...
January 8, 2021
Nawah Scientific begins 2021 with $1 million (€0.82M) in additional funds. The Cairo-based health tech startup has secured a second pre-series A fundraise comprising both equity and debt, it announced in a press statement late on 7 Jan.
Funded primarily by Egypt Ventures, the round also saw contributions from the Alexandria Fund, Cairo Angels, Alex Angels, undisclosed angels from Hult...